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Mammary tumors are the most frequent neoplastic pro-
cesses of the female dog and represent a problem of large
impact in veterinary medicine. In this context, many
efforts are being directed towards adopting criteria
towards standardization of the diagnosis, understanding
behavior and tumor evolution and evaluating prognostic
and predictive factors such as: morphology, oncogenes
expression and genetic alterations. The knowledge and
adoption of these parameters are fundamentally important
for choice and success of therapies that promote reduction
of tumoral recurrence and increase in global survival. In
addition, mammary tumors of female dog present epide-
miological, clinical, biological and genetic similarities with
mammary neoplasms in women and are therefore consid-
ered important models in comparative studies. The aim of
our group is to evaluate clinical, morphological and mole-
cular aspects of canine mammary tumors in order to iden-
tify comparative aspects with human breast cancer.
Canine mammary tumors using TNM staging, histological
grade, mitotic count and veterinary and human classifica-
tions were compared and reviewed. Results demonstrate
that mammary tumor types in human and dogs are simi-
lar, although the relative frequency of each tumor type is
different. Using immunohistochemical methodology, was
standardized a series of specific human antigen antibodies
in canine tissue. The antibodies were selected based on
their ability to classify tumor types and to provide prog-
nostic and predictive information previously described in
human breast cancer studies. Results show that the
expression of most markers is similar in benign and malig-
nant mammary tumors in both species. It was also evalu-
ated the prognostic value of mitotic index and histological
malignancy grade demonstrating a sound correlation
between those methods and the prognostic factors like in
human breast cancer studies. Studies with found the Her-
2 expression to be positively associated with nuclear
pleomorphism, histological grade and mitotic count. Posi-
tive association was found between nuclear pleomorphism
and MIB-1 index. These results imply that some tumor
biological and morphological characteristics are associated
with canine mammary gland tumors as it has been seen in
human breast cancer. Studying benign non-neoplastic
lesions was verified that they are pathologically and immu-
nophenotypically similar to those in the human breast. In
our diagnostic routine, mixed tumours are the most com-
mon tumour types in the female canine mammary gland.
These tumours exhibit a complex histological pattern due
to the presence of epithelial and mesenchymal elements
and have the capacity to undergo malignant transforma-
tion, resulting in carcinomas. The origin of the several
mixed tumour components is a subject of a long-standing
controversy and is not yet fully understood. A suggested
hypothesis states that these components originate from
stem cells with a high divergence capability. This assump-
tion is grounded on immunohistochemical studies and on
the observation that the epithelial and mesenchymal com-
ponents of mixed tumours are monoclonal. Carcinomas in
benign mixed tumors (CBMT) are the most common
malignant tumor in female dogs and may serve as a model
for studies on tumor progression. Versican expression in
in situ and invasive carcinomatous areas of CBMT was
evaluated, verifying possible associations with other classic
prognostic factors and overall survival. Results suggest
that, as the myoepithelium gains mesenchymal character-
istics, a decrease in p63 and a-SMA molecule expression
and increase in versican expression occurs. In addition,
the direct relation between versican and invasion suggests
the role of this molecule in tumor progression. In CBMT
were also investigated morphological aspects and their
immunophenotypical profiles, through an immunohisto-
chemical panel based on five molecular markers (ER, PR,
HER2, CK5 and EGFR). It was concluded that CBMT are
predominantly characterized as low-grade malignancy
neoplasms. The various immunophenotypic profiles sug-
gest the origin of these lesions in more than one cell type
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(luminal and myoepithelial). Invasive micropapillary carci-
noma (IMPCa) of the mammary gland was first described
by our group and should be highlighted. Despite its rare
occurrence in humans and dogs, it has a distinct aggres-
sive behaviour and poor prognosis. Were evaluated clini-
copathological and immunophenotypical characteristics as
well as the overall survival of canine IMPCa. Findings
demonstrate that canine IMPCas are similar to human
IMPCas, presenting aggressive behaviour with high rates
of metastasis to regional lymph nodes and short overall
survival and should be considered important lesions of
the mammary gland in dogs. The distribution and inten-
sity of lymphocytic responses in canine mammary tumors,
in particular the relative abundance of the lymphocyte
subpopulations which define whether the inflammatory
process will act as a promoter or inhibitor of tumor devel-
opment and metastasis were analyzed. Morphologic and
immunohistochemical studies should be related with clini-
cal aspects and serve as prognostics and predictive mar-
kers. Then patients suffering from mammary tumors with
advanced clinical staging were studied. Analyzing the over-
all survival of animals treated only with surgery compared
to those complementarily treated with carboplatin and
Cox-2 inhibitors, the benefit of these patients from com-
plementary therapy was verified. Carboplatin as an only
drug was indicated for treating mammary tumors of
female dogs in advanced clinical staging, with minimal
side effects and easy administration. Limited therapeutic
resources in mammary neoplasms of the female dog, the
confirmed benefits of tamoxifen in human mammary
tumors and insufficient data available on the canine specie
justified a study that addressed additional effects of this
drug in veterinary medicine. Side effects of oral adminis-
tration of tamoxifen in spayed and intact female dogs were
studied and were verified similar side effects to those
observed in women with breast cancer treated with this
medication. It was investigated the potential prognostic
value of serum tumors markers and increased CA15.3 and
LDH serum levels were directly related to the presence of
regional lymph node and distant metastases. CEA showed
no significant change among the groups (healthy, non-
metastatic and metastatic mammary cancer groups). Thus,
we suggest the possibility of using the criteria and the
more extensive experience of human studies for the diag-
nosis and, in the future, treatment, of canine mammary
gland tumors. On the other hand, these results reinforce
the theory that spontaneous canine mammary tumors
may be used as models for studies evaluating the mechan-
isms involved in mammary gland carcinogenesis, develop-
ment of novel cancer therapeutics and may be relevant for
human breast cancer studies.
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